Design of hydralazine hydrochloride matrix tablets based on various polymers and lipids

Indian Journal of Pharmaceutical Education and Research

Volumn 46, Issue 1, 2012, Pages 75-87

  Üner, Melike ^a   Çelebi, Benek ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Controlled release; Hydralazine HCL; Lipids; Matrix tablets; Polymers

Indexed keywords

CARBOMER; GLYCERYL DIBEHENATE; HEXADECANOL; HYDRALAZINE; HYDROXYPROPYLMETHYLCELLULOSE; LIPID; POLYMER; UNCLASSIFIED DRUG;

ACCURACY; ARTICLE; CONTROLLED DRUG RELEASE; DIFFERENTIAL SCANNING CALORIMETRY; DRUG DESIGN; DRUG SOLUBILITY; DRUG STRUCTURE; INFRARED SPECTROSCOPY; MATRIX TABLET; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; TABLET COMPRESSION; TABLET DISINTEGRATION TIME; TABLET FORMULATION; TABLET FRIABILITY; TABLET HARDNESS; TABLET THICKNESS; TENSILE STRENGTH; WEIGHT;

EID: 84858682578     PISSN: 00195464     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Martindale. 31st Edition. London: Royal Pharmaceutical Society; 1996.
2. Estrada Flores L, Duenas Gonzalez A, Borbolla Garcia A, Serna Martinez R, Rivera Hernandez A, Mohar Betancourt A. Inventors; Pharmaceutical composition for the sustained release hydralazine and use thereof as a support for cancer treatment. EP 1 803 447 A1. 2007.
3. Song Y, Zhang C. Hydralazine inhibits human cervical cancer cell growth in vitro in association with APC demethylation and re-expression. Cancer Chemo Pharmacol, 2009; 63: 605-13.
4. Kirsten R, Nelson K, Kirsten D, Heintz B. Clinical pharmacokinetics of vasodilators. Part II. Clin Pharmacokinet, 1998; 35: 9-36.
5. Baveja SK, Ranga Rao KV, Padmalatha Devi K. Zero-order release hydrophilic matrix tablets of adrenergic blockers. Int J Pharm, 1987; 39: 39-45.
6. Steendam R, Lerk CF. Poly(DL-lactic acid) as a direct compression excipient in controlled release tablets: Part I. Compaction behaviour and release characteristics of poly(DLlactic acid) matrix tablets. Int J Pharm, 1998; 175: 33-46.
7. Üner M, Gönüllü Ü, Yener G, Alti{dotless}nkurt T. A new approach for preparing a controlled release ketoprofen tablets by using beeswax. Il Farmaco, 2005; 60: 27-31.
8. Siepmann F, Eckart K, Maschke A, Kolter K, Siepmann J. Modeling drug release from PVAc/PVP matrix tablets. J Control Rel, 2010; 141: 216-22.
9. Carr RL. Evaluating flow properties of solids. Chem Eng, 1965; 18: 163-68.
10. Nunthanid J, Laungtana-anan M, Sriamornsak P, Limmatvapirat S, Puttipipatkhacahorn S, Lim L, Khor E Characterization of chitosan acetate as a binder for sustained release tablets. J Control Rel, 2004; 99: 15-26.
11. Üner M, Alti{dotless}nkurt T. Evaluation of honey locust (Gleditsia triacanthos Linn.) gum as sustaining material in tablet dosage forms. Il Farmaco, 2004; 59: 567-73.
12. Summers MP, Enever RP, Carless JE. Influence of crystal form on tensile strength of compacts of pharmaceutical materials. J Pharm Sci, 1977; 66: 1172-5.
13. Vueba ML, Batista de Carvalho LAE, Veiga F, Sousa JJ, Pina ME. Influence of cellulose ether polymers on ketoprofen release from hydrophilic matrix tablets. Eur J Pharm Biopharm. 2004; 58: 51-9.
14. ICH Harmonised Tripartite Guideline. Validation of analytical procedures: Methodolgy (CPMP/ICH/281/95), 1995.
15. Tatar Ulu S. A new spectrophotometric method for the determination of finasteride tablets. Spectrochim Acta Part A, 2007; 67: 778-83.
16. Higuchi T. Mechanism of sustained-action medication. Theoretical analysis of rate of release of solid drugs dispersed in solid matrices. J Pharm Sci, 1963; 52: 1145-9.
17. Panomsuk SP, Hatanaka T, Aiba T, Katayama K, Koizumi T. A study of the hydrophilic cellulose matrix: Effect of indomethacin and a water-soluble additive on release mechanisms. Chem Pharm Bull, 1995; 43: 994-9.
18. Korsmeyer RW, Gurny R, Doelker E, Buri P, Peppas NA. Mechanisms of potassium chloride release from compressed, hydrophilic, polymeric matrices: effect of entrapped air. J Pharm Sci, 1983; 72: 1189-91.
19. Sriamornsak P, Thirawong N, Korkerd K. Swelling, erosion and release behavior of alginate-based matrix tablets. Eur J Pharm Biopharm, 2007; 66: 435-50.
20. Çelebi B. Hidralazin hidroklorür'ün uzun etkili tabletlerinin hazi{dotless}rlanmasi{dotless} üzerine çali{dotless}smalar [dissertation]. Istanbul: Istanbul Univ.; 2010.
21. Stott OW, Williams AC, Barry BW. Transdermal delivery from eutectic systems: enhanced permeation of a model drug, ibuprofen. J Control Rel, 1998; 50: 297-308.
22. Yener G, Üner M, Gönüllü Ü, Yildirim S, Kiliç P, Saglik Aslan S, Barla A. Design of meloxicam and lornoxicam transdermal patches: Preparation, physical characterization, ex vivo and in vivo studies. Chem Pharm Bull, 2010; 58: 1466-73.
23. Ford JL, Timmins P. Pharmaceutical Thermal Analysis. Chichester: Ellis Horwood; 1989.
24. Orzech CE, Nash NG, Daley RD. Hydralazine hydrochloride. In Florey C, Editor. Analytical profiles of drug substances. Vol. 8., London: Academic Press, Inc.; 1979; p 283-313.
25. Viridén A, Wittgren B, Larsson A. Investigation of critical polymer properties for polymer release and swelling of HPMC matrix tablets. Eur J Pharm Sci, 2009; 36: 297-309.
26. Ghimire M, Hodges LA, Band J et al. In-vitro and in-vivo erosion profiles of hydroxypropylmethylcellulose (HPMC) matrix tablets. J Control Rel, 2010; 147: 70-5.